0.00Open0.00Pre Close0 Volume0 Open Interest25.00Strike Price0.00Turnover5014.91%IV55.18%PremiumMay 17, 2024Expiry Date8.89Intrinsic Value100Multiplier-5DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type-0.8045Delta0.0427Gamma--Leverage Ratio-40.3919Theta0.0000Rho0.00Eff Leverage0.0004Vega
Nurix Therapeutics Stock Discussion
$Taysha Gene Therapies(TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US)$ 14% Clinical programs update
$Jaguar Health(JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US)$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US)$ 0...
Nurix said patients currently enrolled in the trial who are deriving clinical benefit are allowed to continue receiving the current drug product. The screening and enrollment of new patients has been paused.
The company sai...
No comment yet